Posted by Michael Wonder on 07 Jan 2023
Eisai's approach to US pricing for Leqembi (lecanemab), a treatment for early Alzheimer's disease, sets forth out concept of "societal value of medicine" in relation to "price of medicine"
6 January 2023 - Maximising our value for all stakeholders while giving back value to society.
Based on human health care concept, our corporate philosophy, Eisai is committed to improve patients health outcomes and quality of life, simplify care delivery, increase health system efficiency and spur future investments in Alzheimer's disease.
